Refine your search
Collections
Journals
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Chandran, Nisha
- Affordable Healthcare Threatened! Concern for all Stakeholders
Abstract Views :268 |
PDF Views:80
Authors
Affiliations
1 Academy of Scientific and Innovative Research, New Delhi 110 025, IN
1 Academy of Scientific and Innovative Research, New Delhi 110 025, IN
Source
Current Science, Vol 109, No 8 (2015), Pagination: 1375-1376Abstract
No Abstract.Full Text
- Policy as a Driver of Economic Growth:Historical Evidence from the Indian Pharmaceutical Industry
Abstract Views :279 |
PDF Views:87
Authors
Affiliations
1 CSIR-Institute of Genomics and Integrative Biology, New Delhi 110 025, IN
1 CSIR-Institute of Genomics and Integrative Biology, New Delhi 110 025, IN
Source
Current Science, Vol 114, No 06 (2018), Pagination: 1181-1193Abstract
Sound implementation of a well-crafted policy decision allows for technological innovation and sectoral economic proliferation. The rise of the Indian pharmaceutical sector is a classic example in this context. This article aims to trace the evolution of the Indian pharmaceutical industry, highlighting the robust policy decisions favouring the proliferation of the pharmaceutical industry. The national linkages in the form of institutional capacity building and technological improvements have also been focused upon.Keywords
Health Policy, Indian Pharmaceutical Industry History, Open Source, Science Policy History, Science and Technology Policy.Full Text
References
- PwC, P.W.C., India Pharma Inc. Changing Landscape of the Indian Pharma Industry, 2013.
- IBEF, I.B.E.F., Indian Pharmaceuticals Industry Analysis, 2017.
- Curzon, G. N., The Place of India in the Empire: Being an Address Delivered Before the Philosophical Institute of Edinburgh (ed. Murray, J.), University of California Libraries, London, 1909, p. 60.
- Subbarayappa, B. V., Science in India: A Historical Perspective, Rupa Publications, 2014, p. 624.
- Sheriff, M., Materia Medica of Madras, Volume I, Government Press: Madras (India), 1891, p. 81.
- Macaulay, T. B. M. and Young, G. M., Speeches / by Lord Macaulay, with his Minute on Indian education. Selected with an intro. and notes by G. M. Young London, London, 1835.
- Harrison, M., Public Health and Medicine in British India: An Assessment of the British Contribution, in Liverpool Medical History Society Meeting, Cambridge University Press, Liverpool, 1998, pp. 32–48.
- Mushtaq, M. U., Public Health in British India: A brief account of the history of medical services and disease prevention in Colonial India. Indian J. Community Med., 2009, 34(1), 6–14.
- M.o.H.F.W, M.o.H.a.F.W., The Drugs and Cosmetics Act, 1940, D.o. Health, Editor. Government of India, New Delhi, 1940, pp. 1-30.
- Khader, A. F., The Law of Patents – With a Special Focus on Pharmaceuticals in India, LexisNexis Butterworths Wadhwa Nagpur, New Delhi, 2009, p. 771.
- RBI, R.B.o.I., Foreign Collaboration in Indian Industry: Second Survey Report, R.B.o. India, Editor. Bombay, 1985.
- Ghosh, S., Bhagwati-Sen Debate, 2002; http://home.fau.edu/sghosh/web/images/Indiatalk.pdf.
- https://spicyip.com/wp-content/uploads/2013/10/ayyangar_committee_report.pdf
- GOI, G.o.I., Pharmaceutical: Manufacture, Not processing, M.o.C.a. Industry, Editor. 1954: New Delhi.
- https://spicyip.com/wp-content/uploads/2013/10/ayyangar_committee_report.pdf
- http:/pharmaceuticals.gov.in/sites/default/files/Hathi_Committee_report_1975_0.pdf
- http://nppaindia.nic.in
- http://dipp.nic.in/English/Policies/Industrial_policy_statement.pdf
- Sahu, S. K., Globalization and the Indian Pharmaceutical Industry, 2014.
- https://www.rbi.org.in/Scripts/BS_FemaNotifications.aspx?Id=179
- Chaudhuri, S., The WTO and India’s Pharmaceuticals Industry: Patent protection, TRIPS, and Developing Countries, Oxford University Press, New Delhi, 2005,
- Ray, A. S. and Bhaduri, S., Competing Through Technological Capability, CSSP Electronic Working Paper Series, 2012(3).
- Chaturvedi, K. and Chataway, J., Policy and technology co-evolution in the Indian pharmaceutical industry. In Development Policy and Practice Working Paper (ed. Umversity, T. O.), United Kingdom, 2005.
- Taneja, B. et al., An Indian effort towards affordable drugs: generic to designer drugs. Biotechnol. J., 2009, 4(3), 348–360.
- Gokarn, S., Sen, A. and Vaidya, R. R. (eds), The Strcture of Indian Industry, Oxford University Press, 2004.
- Watal, J., Intellectual Property Rights in the WTO and Developing Countries, Springer, 2001.
- Mueller, J. M., The tiger awakens: the tumultuous transformation of India’s patent system and the rise of Indian pharmaceutical innovation. Univ. Pittbg. Law Rev., 2006. 68, 491.
- Abraham, R. M. K. and Wankhar, D. L., Drug Price Control Orders (DPCO), 2015; http://arthapedia.in/index.php?title=Drug_Price_Control_Orders_(DPCO).
- http://pharmaceuticals.gov.in/project/national-pharmaceutical-pricing-policy-2012
- Chaudhuri, S., Intellectual property rights and innovation: MNCs in pharmaceutical industry in India after TRIPS. ISID, Institute for Studies in Industrial Development, 2015.
- Chaudhuri, S., Intellectual Property Rights and Innovation. MNCs in Pharmaceutical Industry in India after TRIPS, in Working Papers, ISID, Institute for Studies in Industrial Development, New Delhi, 2014.
- Unnikrishnan, C. H., Domestic Drug Sales Cross Rs 87,000 crore Despite Pricing Control, 2015; http://www.livemint.com/Politics/HyWhMhav6opaXRdVxd9gnK/Domestic-drug-sales-cross-Rs87000-crore-despite-pricing-con.html
- Joseph, R. K., The R&D Scenario in the Indian Pharmaceutical Industry, 2012.
- PNB, P.N.B. 2017.
- http://dipp.nic.in/English/Schemes/Intellectual_Property_Rights/National_IPR_Policy_08.08.2016.pdf
- Finding Achilles Heel of Drug Resistance in Mycobacterium tuberculosis
Abstract Views :270 |
PDF Views:82
Authors
Affiliations
1 CSIR-Institute of Genomics and Integrative Biology, New Delhi 110 025, IN
2 Academy of Scientific and Innovative Research, New Delhi 110 025, IN
1 CSIR-Institute of Genomics and Integrative Biology, New Delhi 110 025, IN
2 Academy of Scientific and Innovative Research, New Delhi 110 025, IN
Source
Current Science, Vol 114, No 12 (2018), Pagination: 2430-2431Abstract
Tuberculosis (TB), a pulmonary disease caused by Mycobacterium tuberculosis is known to be the second largest cause of death and poses a serious threat to public health throughout the world. Although it can affect immunocompetent people, individuals with weakened immune system (e.g. HIV infection) are at an increased risk.Full Text
References
- Chandran, N., Ph D thesis, Academy of Scientific & Innovative Research, New Delhi, 2018.
- Kaur, D. et al., Sci. Rep., 2017, 7, 46595.
- Vashisht, R., J. Transl. Med., 2015, 13, 83.
- Kaur, D. et al., J. Transl. Med., 2018; 15(1), 261–277.
- Mishra, A. et al., EMBO Mol. Med., 2018, 10, e8038.
- Koul, A. et al., Nature Commun., 2014, 5(3369); doi:10.1038/ncomms4369.
- Xavier, S. A. and Lakshmanan, M., J. Pharmacol. Pharmacother., 2014, 5(3), 222–224.
- Chiang, C. Y., Van, D. A. and Rieder, H. L., Int. J. Tuberc. Lung Dis., 2016, 20(9), 1143–1147.
- Gillespie, S. H., Eur. Respir. Rev., 2016, 25(139), 19–28.
- Manjunatha, U., Boshoff, H. I. M. and Barry, C. E., Commun. Integr. Biol., 2009, 2(3), 215–218.
- Munsiff, S. S., Kambili, C. and Ahuja, S. D., Clin. Infect. Dis., 2006, 43(11), 1468–1475.
- A Decade of OSDD for TB:Role and Outcomes
Abstract Views :262 |
PDF Views:70
Authors
Affiliations
1 CSIR-Institute of Genomics and Integrative Biology (IGIB), New Delhi 110 025, IN
2 Academy of Scientific and Innovative Research (AcSIR), New Delhi 110 025, IN
1 CSIR-Institute of Genomics and Integrative Biology (IGIB), New Delhi 110 025, IN
2 Academy of Scientific and Innovative Research (AcSIR), New Delhi 110 025, IN
Source
Current Science, Vol 115, No 10 (2018), Pagination: 1858-1864Abstract
In this article we estimate the economic benefit of open source drug discovery (OSDD) programme for its decade-long effort of developing newer and novel therapeutics for TB by streamlining the upstream research and development (R&D) of the drug discovery pipeline. The OSDD programme, presently subsumed into the India TB Research and Development Consortium (ITRDC) project led by ICMR, has opened up a novel method of asset utilization and capacity building at a negligible cost, leading to positive economic impact. The OSDD programme has also become an instrumental part of shaping the National Intellectual Property Rights (NIPR) Policy, 2016. This calls for a policy directive as programmes such as OSDD can be a powerful strategy in dealing with the excruciating disease burden of TB and other neglected diseases that countries such as India are facing.Keywords
Drug Discovery, Economic Benefit, ITRDC, India NIPR, Open Source Drug Discovery, Tuberculosis.Full Text
References
- Fenwick, A., The global burden of neglected tropical diseases. Public Health, 2012, 126(3), 233–236.
- Organization, W. H., Investing to Overcome the Global Impact of Neglected Tropical Diseases: Third WHO Report on Neglected Tropical Diseases, World Health Organization, 2015, vol. 3.
- Hotez, P. J. et al., The global burden of disease study 2010: interpretation and implications for the neglected tropical diseases. PLOS Negl. Trop. Dis., 2014, 8(7), e2865.
- UNDP, Humanity Divided: Confronting Inequality in Developing Countries, UNDP New York, eNY NY, 2013.
- Gething, P. and Hay, S., Nations within a Nation: Variations in Epidemiological Rransition Across the States of India, 1990–2016 in the Global Burden of Disease Study, 2017.
- Maurer, S. M., Rai, A. and Sali, A., Finding cures for tropical diseases: is open source an answer? PLOS Med., 2004, 1(3), e56.
- Moran, M., Global funding of new products for neglected tropical diseases. In Causes and Impacts of Neglected Tropical and Zoonotic Diseases: Opportunities for Integrated Intervention Strategies: Workshop Summary, National Academies Press, Washington DC, USA, 2011.
- Von Philipsborn, P. et al., Poverty-related and neglected diseases – an economic and epidemiological analysis of poverty relatedness and neglect in research and development. Glob. Health Action, 2015, 8(1), 25818.
- Pharma, E., World Preview 2018, Dostupnona, 2011; http://www.evaluategroup.com/Public/EvaluatePharma-World-Preview-2018Embracing-the-Patent-Cliff.aspx (30 June 2013).
- Zumla, A. I. et al., New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet Infect. Dis., 2014, 14(4), 327–340.
- Croft, S. L., Neglected tropical diseases in the genomics era: re-evaluating the impact of new drugs and mass drug administration. Genome Biol., 2016, 17(1), 46.
- Paul, S. M. et al., How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nature Rev. Drug Discov., 2010, 9(3), 203.
- Pisano, G. P., Science Business: The Promise, the Reality and the Future of Biotech, Harvard Business Press, 2006.
- Initiative, O. S., Open Source Definition, 2005.
- Williams, S., Free as in Freedom (Paperback): Richard Stallman’s Crusade for Free Software, O’Reilly Media, Inc, 2011.
- DiBona, C., Stone, M. and Cooper, D., Open Sources 2.0: The Continuing Evolution, O’Reilly Media, Inc, 2005.
- Weber, S., The Success of Open Source, Harvard University Press, 2004.
- Russell, J., Supercomputer Sales Drove 2016 HPC Market Up to Record $11.2 Billion, 2017; https://www.hpcwire.com/2017/04/06/supercomputer-sales-drove-2016-hpc-market-record-11-2-billion/
- Nielsen, M., Reinventing Discovery: the New Era of Networked Science, Princeton University Press, 2012.
- DeLano, W. L., The case for open-source software in drug discovery. Drug Discov. Today, 2005, 10(3), 213–217.
- Munos, B., Can open-source R&D reinvigorate drug research? Nature Rev. Drug Discov., 2006, 5(9), 723.
- Masum, H. and Harris, R., Open Source for Neglected Diseases: Magic bullet or Mirage, Results for Development Institute, 2011.
- So, A. D. and Woodhouse, W., Innovation Tackling Antibiotic Resistance Open Source Drug Discovery Initiative in India, Medicine in health systems: Advancing access, affordability and appropirate use. Alliance for Health Policy and Systems Research, World Health Organization, Geneva, 2014, 1st edn, p. 6.
- Bigdeli, M., Peters, D. and Wagner, A., Medicines in Health Systems, World Health Organization, Geneva, 2014.
- Koshy, J., CSIR to Unveil Gene Map for TB on Portal Developed by Infosys, in LiveMint, 2010.
- Singh, S., I Have to Empower the Youth in the CSIR System, in LiveMint, 2008.
- Bhardwaj, A., Scaria, V. and Patra, D., Open source drug discovery: A global collaborative drug discovery model for tuberculosis. Sci. Cult., 2011, 1, 22–26.
- C-DAC. Open Source Drug Discovery, 2017; http://www.garudaindia.in/html/osdd.aspx
- Bhardwaj, A. et al., Open source drug discovery – a new paradigm of collaborative research in tuberculosis drug development. Tuberculosis, 2011, 91(5), 479–486.
- Munos, B., Can open-source drug R&D repower pharmaceutical innovation? Clin. Pharmacol. Ther., 2010, 87(5), 534–536.
- Kelkar, V. et al., Reinventing the CSIR: Report of the Committee to Assess and Evaluate the Outcomes of CSIR Activities, CSIR, Editor, Council of Scientific and Industrial Research (CSIR), New Delhi, 2004.
- Vashisht, R. et al., Systems level mapping of metabolic complexity in Mycobacterium tuberculosis to identify high-value drug targets. J. Trans. Med., 2014, 12(1), 23.
- Vashisht, R. and Brahmachari, S. K., Metformin as a potential combination therapy with existing front-line antibiotics for Tuberculosis. J. Trans. Med., 2015, 13(1), 83.
- Kaur, D. et al., Data intensive genome level analysis for identifying novel, non-toxic drug targets for multi drug resistant Mycobacterium tuberculosis. Sci. Rep., 2017, 7.
- OSDD, Open Source Drug Discovery; www.osdd.net
- Santhosh, R. et al., Open access Mycobacterium tuberculosis clone repository: a community resource by OSDD members. Curr. Sci., 2013. 105(10), 1342–1345.
- Mangal, M. et al., NPACT: naturally occurring plant-based anticancer compound-activity-target database. Nucl. Acids Res., 2012, 41(D1), D1124–D1129.
- Metri, R. et al., SInCRe – structural interactome computational resource for Mycobacterium tuberculosis. Database, 2015, 2015, p. bav060.
- Chandran, N. and Brahmachari, S. K., Technology, knowledge and markets: connecting the dots – electric rickshaw in India as a case study. J. Frugal Innov., 2015, 1(1), p. 3.
- Bureau, P. I., India takes a Lead in TB Research in a Unique Mission Mode to End TB, New Delhi, 2016.